Actively Recruiting
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Led by Asociación para Evitar la Ceguera en México · Updated on 2024-07-31
N/A
Participants Needed
1
Research Sites
904 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
CONDITIONS
Official Title
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Retinopathy of prematurity stages III, IV and V where laser or cryotherapy cannot be used
You will not qualify if you...
- Patients who can be treated with cryotherapy or laser
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Asociación para Evitar la Ceguera en México Hospital "Luis Sanchez Bulnes"
Mexico City, Mexico DF, Mexico, 04030
Actively Recruiting
Research Team
H
Hugo Quiroz-Mercado, MD
CONTACT
M
Maria A Martínez-Castellanos, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here